BOULDER, Colo.--(BUSINESS WIRE)--Array BioPharma Inc. (NASDAQ: ARRY) today announced the presentation of two abstracts which detail positive preclinical data for a novel class of oral, potent and selective checkpoint kinase 1 (Chk1) inhibitors. The data demonstrate that Chk1 inhibition and checkpoint abrogation disrupt natural tumor cell repair mechanisms and suggest that a potent, selective Chk1 inhibitor may bolster the anti-tumor effects of commonly used chemotherapies such as Campostar® (irinotecan), by heightening sensitivity to these DNA damaging agents. Based on the potency, selectivity and efficacy data seen with its Chk1 inhibitors, Array intends to select a compound for development in the first half of 2009. The full posters are available as PDFs on Array’s website at www.arraybiopharma.com.
